Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small cell lung cancer

A. A. Messeih, J. M. Schweitzer, A. Lipton, H. A. Harvey, M. A. Simmonds, J. A. Stryker, J. A. Ricci, S. L. Hoffman, R. J. Gottleib, R. H. Dixon

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

A total of 116 patients with small cell lung cancer were randomized to receive either: cyclophosphamide, 750 mg/m2, doxorubicin, 50 mg/m2, and vincristine, 2 mg iv (Regimen A), or the same drugs plus etoposide, 100 mg/m2 iv daily for 2 days (Regimen B) every 3 weeks. Complete responders received whole-brain radiation therapy. The overall response rates were 50% for Regimen A and 65% for Regimen B (P < 0.05). The complete response rates were 18% for Regimen A and 44% for Regimen B (P < 0.01). For patients with limited disease, the complete responders were 35% on Regimen A and 52% on Regimen B (P = 0.26); for those with extensive disease, the complete responders were 0% on Regimen A and 35% on Regimen B (P = 0.002). The median survival for complete responders was 17 months on Regimen A and 20 months on Regimen B. The difference is not statistically significant. Toxicity was tolerable for both groups; however, it was greater for the etoposide arm. We conclude that although etoposide improves the overall response rates in patients with small cell lung cancer, especially those with extensive disease, the addition of this drug does not lead to improved survival.

Original languageEnglish (US)
Pages (from-to)61-66
Number of pages6
JournalCancer Treatment Reports
Volume71
Issue number1
StatePublished - Mar 25 1987

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small cell lung cancer'. Together they form a unique fingerprint.

Cite this